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background:  Renin-angiotensin-aldosterone system inhibitors (RAASIs), specifically angiotensin-converting enzyme inhibitors (ACEIs) and 
angiotensin receptor blockers (ARBs), are recommended in all patients with acute MI (AMI). Adoption of these recommendations in clinical practice 
among those with renal dysfunction (RDF) is unknown.
methods: From the 24-center TRIUMPH registry, patients admitted with AMI and without any documented contraindications or intolerance to ACEIs 
and/or ARBs were categorized according to admission estimated glomerular filtration rate (eGFR, expressed as ml/min/1.73m2; severe [<30], 
moderate [30-59], mild [60-89] and no [≥90] RDF), or as ESRD. We compared RAASI (either ACEI or ARB) prescription rates at discharge among 
these groups using the Mantel-Haenszel trend test. The impact of baseline eGFR category, as well as that of acute kidney injury (AKI; defined as 
any increase in serum creatinine ≥3mg/dl or ≥50% during hospitalization, over the admission value) and admission EF (<40% or ≥40%) on RAASI 
prescribing was tested, adjusted for demographics and medical history, using a hierarchical modified Poisson model.
results: Of the 4016 total patients (mean age 60±12 years, 67% male, 31% diabetic), unadjusted analysis showed significantly lower RAASI 
prescription rates in those with worse renal function (77.0%, 57.1%, and 66.2% in moderate and severe RDF, and ESRD, respectively, versus 80.9% 
and 80.1% in no and mild RDF, respectively; p<0.001 for trend). After adjusting for the substantial differences across eGFR groups, rate ratios 
(RRs[95% confidence intervals]) were significantly lower in individuals with ESRD (0.81 [0.74-0.89]), severe (0.68 [0.60-0.77]), and moderate 
(0.94 [0.89-0.99]) , but not mild (0.98 [0.96-1.01]) RDF, as compared to no RDF as well as in those with AKI (0.84 [0.79-0.90]). EF <40% was 
independently associated with slightly higher (RR 1.09 [1.01-1.17]) prescription rate at discharge.
Conclusion: Baseline RDF and AKI negatively impact ACEI/ARB prescription at discharge in AMI patients. Whether this partly accounts for the worse 
outcomes of AMI patients with RDF needs to be investigated.
